{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":48,"n_cols":5,"rows_kept":48,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[11,2,11,3],[38,2,38,3],[39,2,39,3],[42,2,42,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910808713803321"]
[null,null,"Autore",null,"Kazmierski Wieslaw M"]
[null,null,"Titolo",null,"Antiviral Drugs : From Basic Discovery Through Clinical Trials"]
[null,null,"Pubbl/distr/stampa",null,"Hoboken, : Wiley, 2011"]
[null,null,"ISBN",null,"1-283-20363-4"]
[{"$nulls":4},"9786613203632"]
[{"$nulls":4},"0-470-92935-9"]
[{"$nulls":4},"0-470-92934-0"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (470 p.)"]
[null,null,"Disciplina",null,"615/.7924"]
[null,null,"Soggetti",null,"Antiviral Agents -- therapeutic use"]
[{"$nulls":4},"Antiviral agents"]
[{"$nulls":4},"Clinical Trials as Topic"]
[{"$nulls":4},"Drug Discovery"]
[{"$nulls":4},"Drug Evaluation"]
[{"$nulls":4},"Epidemiologic Studies"]
[{"$nulls":4},"Chemistry, Pharmaceutical"]
[{"$nulls":4},"Evaluation Studies as Topic"]
[{"$nulls":4},"Investigative Techniques"]
[{"$nulls":4},"Anti-Infective Agents"]
[{"$nulls":4},"Epidemiologic Methods"]
[{"$nulls":4},"Pharmacology"]
[{"$nulls":4},"Therapeutic Uses"]
[{"$nulls":4},"Health Care Evaluation Mechanisms"]
[{"$nulls":4},"Chemistry"]
[{"$nulls":4},"Biological Science Disciplines"]
[{"$nulls":4},"Natural Science Disciplines"]
[{"$nulls":4},"Quality of Health Care"]
[{"$nulls":4},"Public Health"]
[{"$nulls":4},"Pharmacologic Actions"]
[{"$nulls":4},"Environment and Public Health"]
[{"$nulls":4},"Health Care Quality, Access, and Evaluation"]
[{"$nulls":4},"Chemical Actions and Uses"]
[{"$nulls":4},"Delivery of Health Care"]
[{"$nulls":4},"Antiviral Agents"]
[{"$nulls":4},"Health & Biological Sciences"]
[{"$nulls":4},"Pharmacy, Therapeutics, & Pharmacology"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,"Nota di contenuto",null,"ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients"]
[{"$nulls":4},"7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir"]
[{"$nulls":4},"14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection"]
[{"$nulls":4},"21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir"]
[{"$nulls":4},"29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate"]
[null,null,null,"Sommario/riassunto","This book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved antiviral drugs and compounds in advanced clinical development. Organized by a virus (such as HIV, HCV, RSV, influenza, HBV and CMV) and written by top academic and industrial authorities in the field, the book provides a unique opportunity to study, understand and apply discovery and development principles and learning without the need for an individual to research, analyze and synthesize all immense so"]